BNTX241115C120000
- 0.16
- -0.19-54.29%
BioNTech Newsroom
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Goldman Sachs Upgrades BioNTech(BNTX.US) to Buy Rating, Raises Target Price to $137
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Breaking Down BioNTech: 16 Analysts Share Their Views
Vaccine Stocks Drop on Worries About an RFK Jr. Role -- WSJ
BioNTech Is Maintained at Hold by TD Cowen
Why Most Healthcare Stocks Are Falling With Trump's Win, With Some Exceptions
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $110 to $145
Promising Developments in BioNTech's Oncology Pipeline Drive Buy Rating
BioNTech Price Target Cut to $122.00/Share From $132.00 by TD Cowen
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $122 to $171
BioNTech SE (BNTX) Receives a Hold From Oppenheimer
Deutsche Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)
BioNTech SE: Strong Financial Performance and Promising Future Justify Buy Rating
Earnings Call: BioNTech Reports Growth in Oncology and Vaccine Sectors
Cautious Outlook on BioNTech SE: Strong Q3 Performance Overshadowed by Uncertain Future in Vaccine Sales and Oncology Pipeline
Sector Update: Health Care Stocks Retreat Late Afternoon